Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)
Mathew P, Thall P, Johnson M, Oh W, Meluch A, Morris M, Troncoso P, Bucana C, Fidler I, Logothetis C. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Journal Of Clinical Oncology 2006, 24: 4562-4562. DOI: 10.1200/jco.2006.24.18_suppl.4562.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerTime to progressionBone metastasesPlatelet-derived growth factor receptorPartial responseProgressive androgen-independent prostate cancerMetastatic androgen-independent prostate cancerHigh-dose steroid useMedian time to progressionRandomized placebo-controlled double-blind trialGrade 3 AEsMedian overall survivalBone marrow biopsyECOG performance scoreGastrointestinal adverse eventsPerforated sigmoid diverticulitisGrowth factor receptorPerformance scoresWeekly docetaxelProgression-FreeStable diseaseMarrow biopsyTumor responseSigmoid diverticulitisDocetaxel activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply